The per-protocol population (PP population) is a subset of all randomized study participants who adhered fully to the study protocol without major deviations. It includes participants who received the study treatment correctly and to a sufficient extent, attended all required visits, committed no serious protocol violations, and provided evaluable data for the primary endpoint at the time of analysis. The PP population contrasts with the intent-to-treat population (ITT population), which includes all randomized participants regardless of protocol adherence and treatment duration. Both populations provide different but complementary perspectives on the treatment effect. Defining and consistently applying the PP criteria is an essential component of quality assurance in clinical trials and is carefully reviewed during regulatory inspections. <\/p>\n
In frequentist statistics, the intent-to-treat analysis is considered the gold standard for superiority trials because it reflects real-world clinical practice and provides conservative estimates of the treatment effect. If patients do not take the treatment in full, switch therapies, or discontinue the study, these events are accounted for in the ITT analysis, which attenuates the measured effect. The PP analysis, by contrast, shows how well the treatment works when used correctly\u2014i.e., the maximum biologically plausible effect under ideal conditions. <\/p>\n
In practice, both analyses are usually conducted in parallel and the results are compared. If ITT and PP results are consistent, this strengthens the robustness of the conclusions. If they differ substantially, this is an important indication of systematic protocol deviations or selective dropout, which must be discussed in detail in the clinical study report. Regulators regard consistent results from both populations as an important quality indicator of a study. <\/p>\n
In non-inferiority trials, the PP population is of particular importance. In this context, the ITT analysis is not necessarily conservative: if many participants discontinue treatment or switch between groups, the ITT analysis can cause the groups to converge and non-inferiority to be falsely demonstrated\u2014a phenomenon known as dilution bias, which jeopardizes the interpretability of the study. Therefore, the EMA and FDA explicitly require that both the ITT and PP analyses be conducted as co-primary analyses in non-inferiority trials. Non-inferiority is considered demonstrated only if both analyses consistently show a positive result. <\/p>\n
The criteria for exclusion from the PP population must be defined prospectively in the study protocol and in the statistical analysis plan. Typical reasons for exclusion include insufficient treatment duration or compliance (e.g., taking less than 80% of the prescribed doses), use of prohibited concomitant medications, violation of key inclusion or exclusion criteria, and missing primary endpoint measurement. Retrospective definition or modification of these criteria is a serious risk factor for bias and is critically assessed by regulators. <\/p>\n
In practice, deciding which protocol deviations lead to exclusion from the PP population is often not trivial and requires clinical judgment as well as close coordination between the biostatistician, the medical monitor, and the sponsor. To avoid subjectivity, it is advisable to establish an independent, blinded protocol deviation committee that assesses all protocol violations before database lock and finalizes the PP population. This approach is standard particularly for pivotal trials and is recommended in the ICH E9 guideline. <\/p>\n
In marketing authorization procedures, the PP analysis is an indispensable component of the statistical analysis plan and the clinical study report and is specifically reviewed during GCP inspections by the EMA and national authorities. For confirmatory trials, the EMA and FDA require complete documentation of all protocol deviations and the resulting PP population. During inspections, it is assessed whether the PP population was correctly defined and whether the exclusion criteria were applied consistently. Full-service CROs such as mediconomics support sponsors in the prospective definition of PP criteria, the establishment of protocol deviation committees, and the statistical evaluation of both populations in accordance with regulatory requirements. <\/p>\n
Another practical aspect concerns the documentation and tracking of protocol deviations during the study. Deviations captured in real time greatly facilitate subsequent analysis and reduce the risk that important reasons for exclusion from the PP population are overlooked. Many modern clinical trials use electronic systems to record and classify protocol deviations, which automatically generate alerts when defined criteria are violated. These systems are an important component of data quality management and significantly facilitate preparation for database lock and finalization of the PP population. Well-documented deviation management processes are a quality feature that is viewed positively during regulatory inspections. <\/p>\n
Can the PP population be smaller than the ITT population?<\/strong><\/p>\n Yes, almost always. The PP population is a subset of the ITT population because it includes only participants without major protocol deviations. The higher the rate of protocol violations, dropouts, and treatment switches, the smaller the PP population is relative to the ITT population. A very small PP population can substantially limit the statistical power of the PP analysis and lead to results that are not evaluable or are difficult to interpret. This is an important reason to actively promote protocol adherence through close monitoring. <\/p>\n Is the PP analysis always more conservative than the ITT analysis?<\/strong><\/p>\n No. In superiority trials, the ITT analysis is generally more conservative because it includes the dilution effect from non-compliant participants. In non-inferiority trials, the PP analysis can be more conservative because it analyzes stricter, protocol-compliant conditions. Which analysis is more conservative depends on the specific research question, the primary endpoint, and the extent of protocol deviations observed in the study. <\/p>\n","protected":false},"excerpt":{"rendered":" The per-protocol population (PP population) is a subset of all randomized study participants who adhered fully to the study protocol without major deviations. It includes participants who received the study treatment correctly and to a sufficient extent, attended all required visits, committed no serious protocol violations, and provided evaluable data for the primary endpoint at […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6791","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6791\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6791"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}